Summary: New research shows that cannabidiol (CBD) can substantially reduce neuroinflammation linked to Alzheimer’s disease. In experiments using a well-established Alzheimer’s mouse model, scientists observed that inhaled CBD lowered activity of several genes that drive inflammation and reduced levels of harmful proinflammatory molecules in the brain.
The study found that CBD interacts with distinct immune regulators that control inflammatory responses in the central nervous system, indicating a multitarget therapeutic potential. These results suggest CBD could both calm chronic brain inflammation and complement strategies aimed at clearing amyloid plaques and tangles, offering a broader approach to Alzheimer’s therapy.
Key Facts:
- Neuroinflammation Control: Inhaled CBD lowered activation of immune pathways that drive neuroinflammation in an Alzheimer’s mouse model.
- Multitarget Mechanism: CBD engaged multiple immune regulators implicated in inflammation and immune balance within the brain.
- Therapeutic Potential: The findings support CBD as a candidate to both reduce immune overactivation and complement plaque-clearing mechanisms.
Source: SfN
Background: Neuroinflammation contributes to neuronal injury and is increasingly recognized as a central factor in Alzheimer’s disease progression. Cannabidiol (CBD), a non-intoxicating phytocannabinoid, has well-documented anti-inflammatory properties that make it a promising candidate to address this aspect of Alzheimer’s pathology.
In a new paper published in eNeuro, Babak Baban and colleagues at Augusta University examined whether inhaled CBD could modulate neuroinflammatory pathways in the male 5XFAD transgenic mouse model of Alzheimer’s disease. The researchers focused on two key immune-metabolic pathways known to influence neuroinflammation: the indoleamine 2,3-dioxygenase (IDO) pathway and the cyclic GMP-AMP synthase (cGAS) pathway.
Using a combination of flow cytometry, immunofluorescence, gene expression profiling, cytokine assays, and bioinformatics, the research team evaluated how inhaled CBD affected IDO and cGAS expression and downstream inflammatory signaling. The results show that CBD treatment significantly reduced expression of both IDO and cGAS in the brains of 5XFAD mice. These molecular changes correlated with lower levels of proinflammatory cytokines such as TNF-α, IL-1β, and IFN-γ.
Bioinformatic analyses using protein interaction networks helped the researchers prioritize potential CBD targets that could mediate these effects. High-confidence interactions included proteins involved in inflammatory signaling and immune cell function—examples highlighted by the team were AKT1, TRPV1, and GPR55. AKT1 is known to regulate inflammatory cascades and cell survival, TRPV1 influences nociception and neuroinflammation, and GPR55 contributes to immune cell activation and signaling.
Taken together, these findings support a model in which CBD reduces chronic autoinflammation by modulating distinct neuroimmune pathways. Importantly, the authors note that CBD’s effects on inflammation appear to be mechanistically separate from previously reported effects on plaque and tangle clearance, suggesting the compound may offer complementary actions against multiple drivers of Alzheimer’s disease.
“Alzheimer’s research has traditionally focused on amyloid plaques and tau tangles,” says Baban. “Our work emphasizes that chronic autoinflammation is also a core driver of disease. CBD not only calms immune overactivation but may work alongside other mechanisms to promote clearance of pathological proteins. This multitarget profile strengthens its therapeutic potential.”
Key Questions Answered:
A: CBD appears to reduce neuroinflammation by lowering expression of genes and pathways involved in immune overactivation in the brain, thereby decreasing proinflammatory cytokines.
A: The study found that CBD modulates the IDO and cGAS pathways and interacts with immune-related proteins such as AKT1, TRPV1, and GPR55, which together influence neuroinflammatory signaling.
A: It points to a dual-action therapeutic strategy that targets both chronic inflammation and proteinopathy-related processes, potentially offering a broader and complementary approach to current Alzheimer’s interventions.
About this neuropharmacology and Alzheimer’s disease research news
Author: SfN Media
Source: SfN
Contact: SfN Media – SfN
Image: Image credit: Neuroscience News
Original Research: Closed access. “Rethinking Alzheimer’s: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control” by Babak Baban et al., eNeuro. DOI: 10.1523/ENEURO.0114-25.2025
Abstract
Rethinking Alzheimer’s: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control
Alzheimer’s disease has long been linked to amyloid-β plaques and tau tangles, but accumulating evidence highlights the pivotal role of chronic neuroinflammation in disease progression. The autoinflammatory hypothesis proposes that persistent immune dysregulation contributes to neuronal damage, making modulation of immune-metabolic pathways a promising therapeutic strategy.
Cannabidiol (CBD), a non-psychoactive phytocannabinoid with anti-inflammatory effects, may offer therapeutic benefit by targeting neuroimmune regulators. This study examined how inhaled CBD influences two critical neuroinflammatory axes—the indoleamine 2,3-dioxygenase (IDO) pathway and the cyclic GMP-AMP synthase (cGAS) pathway—in the 5XFAD mouse model of Alzheimer’s disease.
Using flow cytometry, immunofluorescence, gene expression analysis, cytokine profiling, and protein interaction bioinformatics, the researchers found that CBD treatment reduced expression of IDO and cGAS and corresponded with lower levels of proinflammatory cytokines such as TNF-α, IL-1β, and IFN-γ. Network analyses highlighted potential interactions between CBD and immune signaling proteins including AKT1, TRPV1, and GPR55, which were prioritized for their known roles in inflammation and high-confidence predicted interactions.
These results support further investigation of CBD as a monotherapy or adjunctive treatment for Alzheimer’s disease, targeting upstream neuroinflammatory drivers. Additional preclinical and clinical studies are required to fully define efficacy, optimal dosing, delivery methods, and safety in humans.